IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

Abstract:

:The functional status of CD4(+) T cells is a critical determinant of antitumor immunity. Polyfunctional CD4(+) T cells possess the ability to concomitantly produce multiple Th1-type cytokines, exhibiting a functional attribute desirable for cancer immunotherapy. However, the mechanisms by which these cells are induced are neither defined nor it is clear if these cells can be used therapeutically to treat cancer. Here, we report that CD4(+) T cells exposed to exogenous IL-7 during antigenic stimulation can acquire a polyfunctional phenotype, characterized by their ability to simultaneously express IFNγ, IL-2, TNFα and granzyme B. This IL-7-driven polyfunctional phenotype was associated with increased histone acetylation in the promoters of the effector genes, indicative of increased chromatin accessibility. Moreover, forced expression of a constitutively active (CA) form of STAT5 recapitulated IL-7 in inducing CD4(+) T-cell polyfunctionality. Conversely, the expression of a dominant negative (DN) form of STAT5 abolished the ability of IL-7 to induce polyfunctional CD4(+) T cells. These in-vitro-generated polyfunctional CD4(+) T cells can traffic to tumor and expand intratumorally in response to immunization. Importantly, adoptive transfer of polyfunctional CD4(+) T cells following lymphodepletive chemotherapy was able to eradicate large established tumors. This beneficial outcome was associated with the occurrence of antigen epitope spreading, activation of the endogenous CD8(+) T cells and persistence of donor CD4(+) T cells exhibiting memory stem cell attributes. These findings indicate that IL-7 signaling can impart polyfunctionality and stemness potential to CD4(+) T cells, revealing a previously unknown property of IL-7 that can be exploited in adoptive T-cell immunotherapy.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Ding ZC,Liu C,Cao Y,Habtetsion T,Kuczma M,Pi W,Kong H,Cacan E,Greer SF,Cui Y,Blazar BR,Munn DH,Zhou G

doi

10.1080/2162402X.2016.1171445

subject

Has Abstract

pub_date

2016-04-25 00:00:00

pages

e1171445

issue

6

eissn

2162-4011

issn

2162-402X

pii

1171445

journal_volume

5

pub_type

杂志文章
  • Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

    abstract::We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.29312

    authors: Pearce OM,Läubli H,Bui J,Varki A

    更新日期:2014-06-25 00:00:00

  • Bcl-2: Live and let die.

    abstract::Recent findings from our laboratory provide the first indication that overexpression of Bcl-2 in Eµ-myc transgenic cells enhances tumor immunosurveillance by inducing NKG2D ligands. Initial evidence suggests that this model is relevant to human patients. Thus, antitumor therapies that target Bcl-2 harbor the risk of r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19536

    authors: Putz EM,Schuster C,Sexl V

    更新日期:2012-08-01 00:00:00

  • Zfra induction of memory anticancer response via a novel immune cell.

    abstract::When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2+ CD3- CD19- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1213935

    authors: Su WP,Wang WJ,Sze CI,Chang NS

    更新日期:2016-07-28 00:00:00

  • A novel strategy for modulation of MDSC to enhance cancer immunotherapy.

    abstract::Myeloid derived suppressor cells (MDSC) suppress anti-tumor immune responses. Our recent publication provides evidence that SHIP-1 plays a prominent role in pancreatic tumor development by regulating MDSC. Therefore, SHIP-1 may be a potential therapeutic target for the treatment of MDSC-related hematological malignanc...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20201

    authors: Ghansah T

    更新日期:2012-09-01 00:00:00

  • Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

    abstract::Amino-bis-phosphonates (N-BPs) such as zoledronate (Zol) have been used in anticancer clinical trials due to their ability to upregulate pyrophosphate accumulation promoting antitumor Vγ9Vδ2 T cells. The butyrophilin 3A (BTN3A, CD277) family, mainly the BTN3A1 isoform, has emerged as an important structure contributin...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1278099

    authors: Zocchi MR,Costa D,Venè R,Tosetti F,Ferrari N,Minghelli S,Benelli R,Scabini S,Romairone E,Catellani S,Profumo A,Poggi A

    更新日期:2017-01-06 00:00:00

  • Trial watch: Oncolytic viruses for cancer therapy.

    abstract::Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while sparing their non-transformed counterp...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.24612

    authors: Vacchelli E,Eggermont A,Sautès-Fridman C,Galon J,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2013-06-01 00:00:00

  • Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.

    abstract::Renal insufficiency is a frequent cancer-associated problem affecting more than half of all cancer patients at the time of diagnosis. To minimize nephrotoxic effects the dosage of anticancer drugs are reduced in these patients, leading to sub-optimal treatment efficacy. Despite the severity of this cancer-associated p...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1320009

    authors: Cedervall J,Dragomir A,Saupe F,Zhang Y,Ärnlöv J,Larsson E,Dimberg A,Larsson A,Olsson AK

    更新日期:2017-04-20 00:00:00

  • Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation.

    abstract::Estrogen receptors have recently been demonstrated at the cell surface. Unlike nuclear receptors, they are able to trigger rapid responses inside the cells. In this study, we evaluated the presence and the possible role of autoantibodies specific to estrogen receptor (anti-ER Abs) in the peripheral blood of breast can...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1074375

    authors: Maselli A,Capoccia S,Pugliese P,Raggi C,Cirulli F,Fabi A,Malorni W,Pierdominici M,Ortona E

    更新日期:2015-08-12 00:00:00

  • Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways.

    abstract::Chronic inflammation can result from inadequate engagement of resolution mechanisms, mainly accomplished by specialized pro-resolving mediators (SPMs) arising from the metabolic activity of lipoxygenases (ALOX5/15) on ω-6 or ω-3 essential polyunsaturated fatty acids (PUFA). We previously demonstrated that formyl pepti...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1293213

    authors: Prevete N,Liotti F,Illiano A,Amoresano A,Pucci P,de Paulis A,Melillo RM

    更新日期:2017-02-21 00:00:00

  • Instruction of myeloid cells by the tumor microenvironment: Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations.

    abstract::The versatility and plasticity of myeloid cell polarization/differentiation has turned out to be crucial in health and disease, and has become the subject of intense investigation during the last years. On one hand, myeloid cells provide a critical contribution to tissue homeostasis and repair. On the other hand, myel...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21566

    authors: Schouppe E,De Baetselier P,Van Ginderachter JA,Sarukhan A

    更新日期:2012-10-01 00:00:00

  • Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.

    abstract::Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the Europ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2020.1777064

    authors: Alcantara M,Du Rusquec P,Romano E

    更新日期:2020-06-10 00:00:00

  • Depletion of B220+NK1.1+ cells enhances the rejection of established melanoma by tumor-specific CD4+ T cells.

    abstract::Five-year survival rates for patients diagnosed with metastatic melanoma are less than 5%. Adoptive cell transfer (ACT) has achieved an objective response of 50% by Response Evaluation Criteria in Solid Tumors (RECIST) in this patient population. For ACT to be maximally effective, the host must first be lymphodepleted...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1019196

    authors: Wilson KA,Goding SR,Neely HR,Harris KM,Antony PA

    更新日期:2015-04-01 00:00:00

  • Tumor-infiltrating podoplanin+ cells in gastric cancer: clinical outcomes and association with immune contexture.

    abstract::Podoplanin (PDPN) has been proved to have significant immunoregulatory effects in several types of malignancies and is considered to be a novel immune checkpoint molecule. However, the clinical significance of PDPN and its potential influence on immune contexture in gastric cancer remain obscure. Here, we aimed to inv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1845038

    authors: Liu X,Cao Y,Lv K,Gu Y,Jin K,He X,Fang H,Fei Y,Shi M,Lin C,Liu H,Li H,He H,Xu J,Li R,Zhang H

    更新日期:2020-11-13 00:00:00

  • Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.

    abstract::Adoptive cell transfer (ACT) is an emerging anticancer therapy that has shown promise in various malignancies. Redirecting antigen specificity by genetically engineering T cells to stably express receptors has become an effective variant of ACT. A novel extension of this approach is to utilize engineered T cells to pr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章,评审

    doi:10.1080/2162402X.2015.1122158

    authors: Tsai AK,Davila E

    更新日期:2016-01-15 00:00:00

  • A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma.

    abstract::Immune responses have been elicited by a variety of cancer vaccines, but seldom induce regressions of established cancers in humans. As a novel therapeutic immunization strategy, we tested the hypothesis that multiple cytokines/chemokines secreted early in secondary responses ex-vivo might mimic the secretory environm...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1386827

    authors: Valentine FT,Golomb FM,Harris M,Roses DF

    更新日期:2017-10-30 00:00:00

  • NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.

    abstract::NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results h...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.21059

    authors: Lai JP,Rosenberg AZ,Miettinen MM,Lee CC

    更新日期:2012-11-01 00:00:00

  • Cancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subset.

    abstract::Circulating fibrocytes were reported to represent a novel myeloid-derived suppressor cell (MDSC) subset and they were also proposed to be involved in the tumor immune escape. This novel fibrocyte subset had a surface phenotype resembling non-monocytic MDSCs (CD14-CD11chiCD123-) and exhibited immunomodulatory roles. Mo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1034918

    authors: Gunaydin G,Kesikli SA,Guc D

    更新日期:2015-05-27 00:00:00

  • Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.

    abstract::Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of ch...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1105431

    authors: van Dodewaard-de Jong JM,Santegoets SJ,van de Ven PM,Versluis J,Verheul HM,de Gruijl TD,Gerritsen WR,van den Eertwegh AJ

    更新日期:2015-12-21 00:00:00

  • ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism.

    abstract::Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components. These changes can directly influence epitope presentation and t...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1336594

    authors: Steinbach A,Winter J,Reuschenbach M,Blatnik R,Klevenz A,Bertrand M,Hoppe S,von Knebel Doeberitz M,Grabowska AK,Riemer AB

    更新日期:2017-06-20 00:00:00

  • Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.

    abstract::Interleukin (IL)-10 is a major cancer-related immunosuppressive factor, exhibiting a unique ability to hamper the maturation of dendritic cells (DCs). We have previously reported that IL-10 induces the conversion of activated, migratory CD1a+ DCs found in the human skin to CD14+CD141+ macrophage-like cells. Here, as a...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23837

    authors: Lindenberg JJ,van de Ven R,Lougheed SM,Zomer A,Santegoets SJ,Griffioen AW,Hooijberg E,van den Eertwegh AJ,Thijssen VL,Scheper RJ,Oosterhoff D,de Gruijl TD

    更新日期:2013-04-01 00:00:00

  • Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells.

    abstract:: Background : Peritoneal carcinomatosis (PC) is a terminal evolution from primary colorectal cancer (pCRC) associated with poor patient survival. Impact of the immune cell infiltrate on PC pathogenesis is unknown. Therefore, we characterized the immunological tumor microenv...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1242543

    authors: Seebauer CT,Brunner S,Glockzin G,Piso P,Ruemmele P,Schlitt HJ,Geissler EK,Fichtner-Feigl S,Kesselring R

    更新日期:2016-10-14 00:00:00

  • Hist-Immune signature: a prognostic factor in colorectal cancer using immunohistochemical slide image analysis.

    abstract::Computerized image analysis for whole-slide images has been shown to improve efficiency, accuracy, and consistency in histopathology evaluations. We aimed to assess whether immunohistochemistry (IHC) image quantitative features can reflect the immune status and provide prognostic information for colorectal cancer pati...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1841935

    authors: Zhao K,Li Z,Li Y,Yao S,Huang Y,Wang Y,Zhang F,Wu L,Chen X,Liang C,Liu Z

    更新日期:2020-10-30 00:00:00

  • Trial Watch: Toll-like receptor agonists for cancer therapy.

    abstract::Toll-like receptors (TLRs) have long been known for their ability to initiate innate immune responses upon exposure to conserved microbial components such as lipopolysaccharide (LPS) and double-stranded RNA. More recently, this family of pattern recognition receptors has been attributed a critical role in the elicitat...

    journal_title:Oncoimmunology

    pub_type: 评审

    doi:10.4161/onci.25238

    authors: Vacchelli E,Eggermont A,Sautès-Fridman C,Galon J,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2013-08-01 00:00:00

  • In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer.

    abstract::Metastatic breast cancer remains an incurable disease. Most patients experience objective treatment responses associated with palliation of symptoms; however, progression inevitably occurs. Thus, there is an urgent need for innovative therapeutic strategies that may halt disease progression. Adoptive T-cell therapy is...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1055061

    authors: Thakur A,Lum LG

    更新日期:2015-07-15 00:00:00

  • Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands.

    abstract::In hepatocellular carcinoma (HCC) patients, the intratumoral expression of Toll-like receptor-3 (TLR3) correlates with prolonged survival. We demonstrated that TLR3 ligands can operate through three independent mechanisms: by directly killing TLR3-expressing cancer cells, by inducing T- and natural killer (NK)-cell in...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23493

    authors: Chew V,Abastado JP

    更新日期:2013-04-01 00:00:00

  • TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

    abstract::Agonistic tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-receptor-specific antibodies are attractive antitumor therapeutics. Recently, our group has generated several human monoclonal antibodies (mAbs) to TRAIL-receptor-1 (TRAIL-R1) (TR1-IgGs) using ISAAC technology. However, these TR1-IgGs did ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1131380

    authors: Piao X,Ozawa T,Hamana H,Shitaoka K,Jin A,Kishi H,Muraguchi A

    更新日期:2016-05-04 00:00:00

  • Chronic activation of DNA damage signals causes tumor immune evasion in the chemoresistant niche.

    abstract::DNA damage responses have been proposed as a gatekeeper to block tumorigenesis. We identify unexpected mechanisms whereby ATM-mediated pathway interacts with NFκB inflammatory cascades, leading to upregulation of integrin-αbβ3 on chemoresistant tumor cells. The integrin-αbβ3 is responsible for impeding tumor-specific ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19123

    authors: Jinushi M

    更新日期:2012-05-01 00:00:00

  • Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.

    abstract::Cutaneous angiosarcoma (CAS) is a malignant sarcoma with poor prognosis. Programmed cell death-1 (PD-1)/programmed cell death-1 ligand-1 (PD-L1) expression reflects antitumor immunity, and is associated with patient prognosis in various cancers. The purpose of this study is to investigate the relationship between PD-1...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1253657

    authors: Honda Y,Otsuka A,Ono S,Yamamoto Y,Seidel JA,Morita S,Hirata M,Kataoka TR,Takenouchi T,Fujii K,Kanekura T,Okubo Y,Takahashi K,Yanagi T,Hoshina D,Hata H,Abe R,Fujimura T,Funakoshi T,Yoshino K,Masuzawa M,Amoh Y,T

    更新日期:2016-11-04 00:00:00

  • mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

    abstract:INTRODUCTION:Vaccination with dendritic cells (DCs) has generally not fulfilled its promise in cancer immunotherapy due to ineffective translation of immune responses into clinical responses. A proposed reason for this is intrinsic immune regulatory mechanisms, such as regulatory T cells (Tregs). A metronomic regimen o...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1207842

    authors: Borch TH,Engell-Noerregaard L,Zeeberg Iversen T,Ellebaek E,Met Ö,Hansen M,Andersen MH,Thor Straten P,Svane IM

    更新日期:2016-07-08 00:00:00

  • Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

    abstract::Prolonged lymphopenia correlating with decreased survival commonly occurs among glioma patients undergoing radiation therapy (RT) and temozolomide (TMZ) treatment. To better understand the pathophysiology of this phenomenon, we prospectively monitored serum cytokine levels and lymphocyte subsets in 15 high-grade gliom...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27357

    authors: Ellsworth S,Balmanoukian A,Kos F,Nirschl CJ,Nirschl TR,Grossman SA,Luznik L,Drake CG

    更新日期:2014-01-01 00:00:00